Ultragenyx Pharmaceutical Inc. (RARE) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Ultragenyx Pharmaceutical Inc.
Address
60 Leveroni Court
Novato, CA 94949
United States of America (the)
Phone
415 483 8800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
1371
First IPO Date
January 31, 2014
Key Executives
| Name | Title | Pay | Year Born |
| Emil D. Kakkis | Founder, President, Chief Executive Officer & Director | 1.19M | 1960 |
| Dennis Karl Huang | Chief Technical Operations Officer and Executive Vice President of Gene Therapy Operations | 331,330 | 1965 |
| Karah Herdman Parschauer | Chief Legal Officer & Executive Vice President of Corporate Affairs | 819,872 | 1978 |
| Howard Horn | Executive Vice President of Corporate Strategy & Chief Financial Officer | 846,010 | 1979 |
| Eric Crombez | Chief Medical Officer & Executive Vice President | 882,356 | 1973 |
| John Richard Pinion | Chief Quality Operations Officer & Executive Vice President of Translational Sciences | 923,934 | 1966 |
| Erik Harris | Executive Vice President & Chief Commercial Officer | 925,255 | 1970 |
| Aaron Olsen | Senior Vice President of Corporate Strategy & Finance | 0 | N/A |
| Ernie W. Meyer | Chief Human Resources Officer & Executive Vice President | 0 | 1965 |
| Theodore A. Huizenga | Senior Vice President, Corporate Controller & Principal Accounting Officer | 0 | 1971 |
| Vimal Srivastava | Senior Vice President of Business Development & Alliance Management | 0 | 1965 |
Description
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
